

# Corporate Action Notice



August 2, 2019

## Ratio Change and Reverse Split

### Genetics Technologies Limited

ADR CUSIP: 37185R208

ADR ISIN: US37185R2085

ADS Ticker Symbol: GENE

Ratio (DRs: Underlying Shares): 1:150

BNY Mellon, at the direction of Genetic Technologies Limited, is announcing a ratio change on the American Depositary Receipt ("ADR") program from one (1) American Depositary Share ("ADS") representing one hundred fifty (150) ordinary shares to a new ratio of one (1) ADS representing six hundred (600) ordinary shares.

The ratio change will result in a reverse split on the Genetic Technologies ADSs on the basis of one (1) new ADS for every four (4) old ADSs held. The ordinary shares of Genetic Technologies Limited will not be affected by this change in the ADS to ordinary share ratio.

Effective August 15, 2019, ADS holders of Genetic Technologies Limited will be required on a mandatory basis to surrender their old ADSs to BNY Mellon for cancellation at the rate of four (4) "OLD" ADSs (CUSIP 37185R208) for one (1) "NEW" ADS (CUSIP 37185R307). Holders in the Direct Registration System and in DTC will have their ADSs automatically exchanged and need not take any action. Only whole ADSs will be distributed. BNY Mellon will attempt to sell any fractional ADSs and distribute the cash proceeds.

#### Please note below the timetable for the reverse stock split:

Effective date:	August 15, 2019
Old CUSIP:	37185R208
Old Ratio:	1 DS: 150 Ordinary shares
Exchange Ratio:	1 "New" ADS for every 4 "Old" ADSs
New CUSIP:	37185R307
New Ratio:	1 ADS: 600 Ordinary shares

**Please note: A ratio change may impact the fees payable by DR investors.**

BNY Mellon's books will be closed for all issuance and cancellation transactions on CUSIP 37185R208 from the close of business August 14, 2019. BNY Mellon anticipates that on August 15, 2019, the books will be opened for all issuance and cancellation transactions on CUSIP 37185R307.

To learn more about Depositary Receipts, please contact [DRBrokerSolutions@bnymellon.com](mailto:DRBrokerSolutions@bnymellon.com) or visit our website at [adrbnymellon.com](http://adrbnymellon.com).

**PLEASE SEE INVESTOR DISCLOSURE ON LAST PAGE.**

## Investor Disclosure

This notice and the information and data provided herein are provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data. BNY Mellon does not undertake any obligation to update or amend this notice or any information or data, and may change, update or amend this notice or any information or data at any time without prior notice.

BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such. We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon this notice or any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates; in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at [https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset\\_upload\\_file49220\\_197380.pdf](https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf).

This notice or any excerpt of this notice may not be copied or reproduced without the prior express written consent of BNY Mellon.

BNY Mellon is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

BNY Mellon's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY Mellon.

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY MELLON AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

